Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safe

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. HOOD
7. DFTX
8. GOOGL
9. MU
10. IBM

Go back to Invivyd Announces First Participants Dosed in LIBERTY, a Phase 3 Clinical Trial to Evaluate the Safety and Tolerability of VYD2311 Antibody Versus mRNA COVID Vaccine and to Characterize the Safe
(NASDAQ: IVVD) Delayed: 0.91 -0.06 (6.19%)
Previous Close $0.97    52 Week High $ 
Open $0.96    52 Week Low $ 
Day High $0.99    P/E N/A 
Day Low $0.91    EPS $ 
Volume 4,104,925       

(NASDAQ: IVVD) Delayed: 0.91 -0.06 (6.19%)
Previous Close $0.97    52 Week High $ 
Open $0.96    52 Week Low $ 
Day High $0.99    P/E N/A 
Day Low $0.91    EPS $ 
Volume 4,104,925